
PREpare Overseas
Nov 10, 2023
DEADLINE: November 19, 2023
The project
Acute myeloid leukemia (AML) is a devastating disease with dismal five-year overall survival rates. Despite the introduction of novel treatments, therapy resistance remains a major problem in achieving cures for AML patients.
The drug venetoclax, a BH3-mimetic that targets the pro-survival protein BCL2, has shown promise for AML treatment, especially when combined with azacitidine, an epigenetic therapeutic. However, resistance to this combination is a major problem, necessitating a deeper understanding of the underlying mechanisms and the development of strategies to overcome it.
Since no DNA mutations were found in AML cells upon acquired venetoclax resistance, we will investigate in this project if non-genetic changes drive venetoclax resistance in AML. Applying single-cell and bulk sequencing methods to AML cells should lead to a detailed understanding of the molecular basis of leukemia cell plasticity in response to venetoclax and/or epigenetic therapy. Elucidating why it might occur and, importantly, if it could be recognized and prevented. This project should significantly improve outcomes for patients with AML.
Let’s meet!
IInterested applicants should submit an electronic copy of their CV, the names and contact information of 2 referents, and a cover letter describing past research experience and addressing the key selection criteria, current research interests and career goals.
During the publication period, applications will be handled continuously. If the vacancy is filled, it will be closed prematurely.
If you have any questions about this position, please feel free to contact Dr. Rachel Thijssen, via r.thijssen@amsterdamumc.nl.
For more information about the application procedure, please contact Tanja Hart, Recruitment advisor, via 06-21603178 or via recruitment@amsterdamumc.nl.
A reference check, screening and hiring test may be part of the procedure. Read here whether that applies to you. If you join us, we ask you for a VOG (Certificate of Good Conduct).
Internal candidates will be given priority over external candidates in case of equal suitability.
Acquisition in response to this vacancy is not appreciated.
Check more information on the link: